Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to control ovarian cancer and reduce painful fluid buildup

NCT ID NCT04919629

Recruiting now Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adults with these cancers will be randomly assigned to one of three treatment groups. The goal is to see if the combinations reduce fluid accumulation and improve survival compared to bevacizumab alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinosarcoma fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian carcinosarcoma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CARCINOSARCOMA FALLOPIAN TUBE CLEAR CELL ADENOCARCINOMA FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE SEROUS ADENOCARCINOMA OVARIAN CARCINOSARCOMA OVARIAN CLEAR CELL ADENOCARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN SEROUS ADENOCARCINOMA PRIMARY PERITONEAL CARCINOSARCOMA PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA PRIMARY PERITONEAL SEROUS ADENOCARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    RECRUITING

    Buffalo, New York, 14263, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact